The antiaggregatory effect of ticagrelor may persist up to 5 days despite its reversible nature of P2Y12 receptor inhibition. As a result of irreversible inhibition of platelet P2Y12 receptors, the antiplatelet action of clopidogrel and prasugrel is prolonged for the lifespan of thrombocytes and lasts up to 7 days. Antiaggregatory treatment reduces ischemic events, but at cost of increased bleeding rates. It is based on dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor inhibitor. Trial Registration: Not applicable.Īntiplatelet treatment is one of the pillars of contemporary therapy in acute coronary syndromes. However, a higher prevalence of ICH bleeds was noted in the andexanet alfa group. Conclusions: Anticoagulant reversal therapy with idarucizumab was associated with significantly lower adjusted mean total hospital and ICU costs compared with andexanet alfa. Results: Idarucizumab patients were older than andexanet alfa patients (median age 81 vs 77 years p < 0.001), and less likely to experience intracranial hemorrhage (ICH) (37.1%vs 73.8% p = 0.001).
Inverse of treatment probability weighting (IPTW) method was used to balance patient and clinical characteristics between treatment cohorts. Methods: This retrospective study utilizing Premier Healthcare Database (PHD) included patients aged ≥18 years on direct oral anticoagulants (DOACs) who experienced life-threatening bleeds, discharged from the hospital during -, and received idarucizumab or andexanet alfa. Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors.
0 kommentar(er)
